Followers | 798 |
Posts | 118388 |
Boards Moderated | 0 |
Alias Born | 11/20/2004 |
Monday, November 02, 2020 4:40:27 PM
RESEARCH TRIANGLE PARK, N.C, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced it has rescheduled its special meeting of stockholders, which was originally scheduled for October 21, 2020, to be held at 4:30 p.m., Eastern Time, on November 13, 2020. The special meeting will be a virtual meeting conducted solely online via live webcast and can be attended by visiting www.meetingcenter.io/287587626.
As previously announced, on October 16, 2020, the Company received an unsolicited offer to enter into a License Agreement for the Company’s LIQ861 product candidate (the “Alternative Proposal”). The Alternative Proposal was conditioned upon the Company terminating the Agreement and Plan of Merger, dated as of June 29, 2020, by and among the Company, RareGen, LLC, Liquidia Corporation, Gemini Merger Sub I, Inc., Gemini Merger Sub II, LLC, and PBM RG Holdings, LLC (the “Merger Agreement”). On November 1, 2020, the Company’s board of directors (the “Board of Directors”) has determined that the Alternative Proposal does not constitute a Superior Proposal and the Company subsequently informed the counterparty that it is terminating discussions with respect to such Alternative Proposal.
Accordingly, the Board of Directors has unanimously reaffirmed its recommendations that the Company’s stockholders vote “FOR” each proposal being submitted to a vote of the Company’s stockholders at the Special Meeting.
Recent LQDA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 10:27:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 10:25:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/08/2024 04:15:08 AM
- Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) • GlobeNewswire Inc. • 06/18/2024 12:42:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 01:25:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 01:24:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:30:28 AM
- District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 09:00:48 PM
- Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:30:43 PM
- Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 09:43:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 09:10:36 PM
- Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD • GlobeNewswire Inc. • 05/10/2024 12:00:00 PM
- Liquidia Corporation to Present at BofA Securities Health Care Conference 2024 • GlobeNewswire Inc. • 05/07/2024 12:30:00 PM
- Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 01:00:10 PM
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder • GlobeNewswire Inc. • 04/01/2024 10:00:44 AM
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 10:00:00 AM
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 • GlobeNewswire Inc. • 03/06/2024 11:30:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:07:54 AM
- Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress • GlobeNewswire Inc. • 01/30/2024 11:30:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 12:01:42 PM
- Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder • GlobeNewswire Inc. • 01/25/2024 11:00:57 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM